PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
1 July - 30 September 2023
Summary of the Interim Report
Net sales of 0.6 MSEK (0.0 MSEK)
Other income amounted to 0.0 MSEK (0.0 MSEK)
Third quarter of 2023
- R&D costs for the period amounted to 7.4 MSEK (10.9 MSEK)
- Profit after tax amounted to -10.8 MSEK (16.1 MSEK) ∞ Earnings per share for the quarter amounted to -0.10 SEK (-0.27 SEK)
- Cash flow from operating activities amounted to -7.3 MSEK (-3.6 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 2.3 MSEK (6.7 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 50.7 MSEK (39.3 MSEK)
The period January-September 2023
- Net sales of 7.1 MSEK (3.7 MSEK)
- Other income amounted to 0.3 MSEK (0.4 MSEK)
- R&D costs for the period amounted to 23.0 MSEK (42.7 MSEK)
- Profit after tax amounted to -26.3 MSEK (-50.9 MSEK)
- Earnings per share for the quarter amounted to -0.27 SEK (-0.88 SEK)
- Cash flow from operating activities amounted to -18.6 MSEK (-39.1 MSEK)